IN8BIO, INC.
Close on Oct 19, 2026
- Market cap
- $21.22M
- P/E (TTM)
- –
- Dividend yield
- –
About In8bio
Biological Products, (No Diagnostic Substances), SIC 2836
IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers. The company develops ex vivo expanded, activated, and genetically engineered gamma-delta T cell therapies using its DeltEx platform to treat cancer and autoimmune diseases. Its therapeutic programs evaluate allogeneic, autologous, and stem-cell-derived approaches, as well as T cell engagers designed to selectively direct gamma-delta T cells against target cells. The company does not currently have commercial products and develops its treatments to serve patients suffering from hematologic cancers, solid tumors, and autoimmune conditions.
The company operates clinical and preclinical development programs within the United States. Its lead cellular therapy candidates undergo evaluation across multiple American medical centers, including the Kansas University Cancer Center and The Ohio State University. IN8bio maintains its principal executive offices in New York, New York.
Summary of the business section of In8bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- IN8BIO, INC.
- Headquarters
- New York, NY
- Address
- Empire State Building, 350 5th Avenue, Suite 5330 10118
- Phone
- (646) 600-6438
- Website
- in8bio.com
- Employees
- 17, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- CohnReznick LLP, New York, New York
Stock & identifiers
- Ticker
- INAB
- Exchange
- Nasdaq
- IPO date
- Jul 30, 2021
- Shares outstanding
- 10M, Aug 3, 2026
- Public float
- $7.60M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-30 reverse, Aug 7, 2025; 1-for-30 reverse, Jun 6, 2025
- SEC CIK
- 1740279
- CUSIP
- 45674E208
- ISIN
- US45674E2081
- LEI
- 549300H68IVCRKSGSL94
- EIN
- 82-5462585
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| William Tai-Wei Ho | CEO, Director | 124,817 |
| Kate Rochlin | President and COO | 9,085 |
| Patrick McCall | CHIEF FINANCIAL OFFICER | 9,482 |
| Lawrence Lamb | EVP and CSO | 101,369 |
| Emily Fairbairn | Director | 0 |
| Luba Greenwood | Director | 7,826 |
| Peter C. Brandt | Director | 98,690 |
| Jeremy R. Graff | Director | 4,549 |
| Corinne Epperly | Director | 81,967 |
| Alan S. Roemer | Director | 49,514 |
| Travis Whitfill | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 17 full-time employees, of whom 13 were primarily engaged in research and development activities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 7, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 30, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 10, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
| Sep 20, 2018 | Name change | Name changed from Incysus Therapeutics, Inc. to IN8BIO, INC. |